Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | STK17B | O94768 | 2/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | S100A9 | P06702 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
| ▸ | BCR | P11274 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3450121 | 0.85 | STK17B (0.40) | MEN1KMT2ASTK17BSTK17AALDH1A1 | |
| SCHEMBL13649018 | 0.81 | KMT2A (0.41) | MEN1KMT2ASTK17BSTK17AALDH1A1 | |
| SCHEMBL29474434 | 0.79 | STK17B (0.39) | MEN1KMT2ASTK17BSTK17AALDH1A1 | |
| SCHEMBL13649017 | 0.79 | ALDH1A1 (0.42) | MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL13194676 | 0.78 | KMT2A (0.46) | MEN1KMT2ASTK17BSTK17AALDH1A1 | |
| SCHEMBL16570401 | 0.78 | MEN1 (0.44) | MEN1KMT2ASTK17BSTK17AALDH1A1 | |
| SCHEMBL27635199 | 0.77 | SIRT5 (0.46) | MEN1KMT2ASTK17BSTK17AALDH1A1 | |
| SCHEMBL13655334 | 0.76 | MEN1 (0.38) | MEN1KMT2ASTK17BSTK17AALDH1A1 | |
| SCHEMBL17595892 | 0.76 | STK17A (0.41) | MEN1KMT2ASTK17BSTK17AALDH1A1 | |
| SCHEMBL5151737 | 0.76 | STK17A (0.50) | MEN1KMT2APRKCISTK17BSTK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108561-B | Heteroaryl compounds as IRAK inhibitors and uses thereof | 默克专利有限公司 | 2020-08-28 | — | — | CN | disclosed |
| EP-3221306-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-11-13 | — | — | EP | disclosed |
| US-10030013-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2018-07-24 | — | — | US | disclosed |
| US-20180002327-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-01-04 | — | — | US | disclosed |
| US-9790221-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-10-17 | — | — | US | disclosed |
| EP-3221306-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-20160145252-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-05-26 | — | — | US | disclosed |
| WO-2016081679-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-05-26 | — | — | WO | disclosed |
| US-7312225-B2 | Macrocyclic pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-12-25 | — | — | US | disclosed |
| US-20040209895-A1 | inhibit cyclin-dependent kinases and VEGF-receptor tyrosine kinases | SCHERING AG (DE) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209895-A1 | inhibit cyclin-dependent kinases and VEGF-receptor tyrosine kinases | CCNK, CDK2, CDK1 | MEN1 2527/4885KMT2A 3155/4885PRKCI 523/4885 |
| US-10030013-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | MEN1 3661/4885KMT2A 855/4885PRKCI 292/4885 |
| US-20160145252-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 3661/4885KMT2A 855/4885PRKCI 292/4885 |
| US-20180002327-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 3661/4885KMT2A 855/4885PRKCI 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.